Article thumbnail

Up-regulation of fas reverses cisplatin resistance of human small cell lung cancer cells

By Wei Wu, Hai-dong Wang, Wei Guo, Kang Yang, Yun-ping Zhao, Yao-guang Jiang and Ping He
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2877011
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1990). Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cell
  2. (2005). Augmented expression of metallothionein and glutathione Stransferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch
  3. (2010). BR: Glutathione S-transferase pi amplification is associated with cisplatin Received:
  4. (1994). Cell biological mechanism of multidrug resistance in tumors.
  5. (1999). Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil. Oncol Rep
  6. (2000). Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells [J]. Oncology
  7. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene
  8. (2004). Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer. Ai Zheng
  9. (1997). Debatin K-M: Crossresistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/ced-3 proteases). Blood
  10. (1996). Debatin KM: Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med
  11. (2002). Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res
  12. (1997). Dimanche-Boitrel MT: Sensitization of cancer cells treated with cytotoxic drugs to Fasmediated cytotoxicity.
  13. (1999). Eberlein TJ: Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery
  14. (2005). Etxaniz O: Applications of genomics in NSCLC. Lung Cancer
  15. (1994). Fas and Fas ligand: a death factor and its receptor. Adv Immunol
  16. (1996). Fesik SW: NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature
  17. (1994). FL: Construction and propagation of human adenovirus vectors.
  18. (1998). Glutathione S-transferase pi immunostaining of cisplatin-resistant ovarian cancer cells in ascites. Acta Cytol
  19. (2005). HJ: Small interfering RNAinduced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun
  20. (1998). Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas mediated apoptosis. Cancer Res
  21. (2001). ID: Glutathioneassociated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy.
  22. (1996). Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy
  23. (2004). Köberle B: Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines.
  24. (2010). Legembre Patrick: Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells? Recent Patents on Anti-Cancer Drug Discovery
  25. (2004). Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells[J].
  26. (1994). Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
  27. (2002). Ng IO: Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Cancer Letters
  28. (2003). Nucleotide excision repair pathways involved in Cisplatin resistance in non-smallcell lung cancer. Cancer Control
  29. (2010). Paul: Cisplatin Enhances Protein Kinase R-Like Endoplasmic Reticulum Kinase- and CD95-Dependent Melanoma DifferentiationAssociated Gene-7/Interleukin-24-Induced Killing in Ovarian Carcinoma Cells. Mol Pharmacol
  30. (1998). PH: p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs.
  31. (1998). Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev
  32. (1997). PR: Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.
  33. (2009). Ramp Uwe, Bier Henning: Is there a role for the Fas-/Fas-Ligand pathway in chemoresistance of human squamous cell carcinomas of the head and neck (SCCHN)? Oral Oncology
  34. (1992). RD: An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc Natl Acad Sci USA
  35. (2000). Reed E: Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res
  36. (2000). Rittgen W: Cellular predictive factors for the drug response of lung cancer. Anticancer Res
  37. (1992). S: The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen.
  38. (1997). Stahnke K: Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction. Biochem Soc Trans
  39. (2004). Tsukuda M: The relationship of the human glutathione S-transferase PI polymorphism and chemotherapeutic sensitivity in head and neck squamous carcinoma.
  40. (1992). VA: Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol